CEACAM-8

CEACAM-8

CEACAM-8 詳細

Molecule Name
Non specific cross-reacting antigen 95
分子の別称
CEACAM8,CD66b,CD67,CGM6,NCA-95
Drug Development Progress
治験薬の数1
市販薬剤の数1
研究&開発段階Approved
ターゲットの別称
Non-specific cross-reacting antigen NCA-95,CGM6,Carcinoembryonic Antigen Gene Family Member 6,CD66b Antigen,NCA-95,CD67,Carcinoembryonic antigen CGM6,CD66b,CEACAM8,Carcinoembryonic Antigen Related Cell Adhesion Molecule 8,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 8,CD67 Antigen,CEA Cell Adhesion Molecule 8
バックグランド
Carcinoembryonic antigen-related cell adhesion molecule 8 (CEACAM8) is also known as CD66b (Cluster of Differentiation 66b), CD66b, CD67, CGM6, NCA-95, and is one of seven human CEACAM family members within the immunoglobulin superfamily. CEACAM family members are a set of widely expressed proteins involved in several biological functions, including cell adhesion, migration, signal transduction, and the regulation of gene expression. Abnormal overexpression and downregulation of some CEACAMs have been described in tumor cells. In humans, CEACAMs include type I transmembrane proteins (CEACAM1, CEACAM3, and CEACAM4) and GPI-linked molecules (CEACAM5 through CEACAM8). There is no human CEACAM2. CEACAM8 is a single chain, two Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. It is an activation marker for human granulocytes.

CEACAM-8 製品リスト

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
90Y-DTPA-besilesomabTLX-66Phase 2 ClinicalTelix Pharmaceuticals Ltd
Multiple Myeloma; Neoplasms, Plasma Cell; Plasmacytoma
詳細

市販薬剤に関する情報

英語名研究コード研究開発ステージ会社オリジナル製品名最初に承認をした国最初の適応症最初に承認を受けた会社承認された日付適応症臨床試験
Besilesomab99Tcm-BW250-183; TLX-66-CDx; TLX66-CDx; BW-250-183ApprovedCis Bio International SaScintimunEUOsteomyelitisCis Bio International Sa2010-01-11
Osteomyelitis
詳細